



EMIF Deliverable 6.3: Select ≤ 6 candidate biomarkers and measure in $\leq 20K$ overweight/obese individuals

Executive summary

Executive Summary

We are measuring six candidate biomarkers including four pro-inflammatory cytokines in a total of 23,500 individuals from the EPIC-Norfolk and Fenland cohort studies using a high-sensitivity immunoassay platform. The biomarkers were selected on the basis of an extensive options appraisal. Full results are expected to become available in the first quarter of 2016 and will be used to conduct Mendelian randomisation analyses of these blood biomarkers and risk of the metabolic complications of obesity.

Contacts

EMIF-Metabolic: Dawn Waterworth and Ulf Smith
Dawn.M.Waterworth@gsk.com / ulf.smith@medic.gu.se